Nebraska Medicaid and tirzepatide
Zepbound for weight loss: no. Only covered for moderate to severe sleep apnea in adults 18 and older. Prior authorization required. Mounjaro for weight loss: no. Non-preferred drug in the diabetes class. Requires a diabetes diagnosis and trials of two preferred drugs.; for type 2 diabetes Nebraska Medicaid must cover it. Read from Nebraska Department of Health and Human Services, Medicaid pharmacy program (Prime Therapeutics) documents Nov 6, 2026.
Zepbound · Nebraska DHHS Medicaid, via Prime Therapeutics State Government Solutions
“Tirzepatide (Zepbound) is only covered for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults aged at least 18 years.”
read Nov 6, 2026
Mounjaro · Nebraska DHHS Medicaid, via Prime Therapeutics State Government Solutions
“Diagnosis of diabetes with HbA1C ≥ 7 AND”
read Nov 6, 2026
In 2025 Nebraska Medicaid paid for 6,041 tirzepatide prescriptions (Mounjaro, Zepbound), 16% of its GLP-1 prescriptions and 40th of the 50 states and DC. It reimbursed $5.9 million before rebates, $969 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 5,686 | $5.5 million | $966 |
| Zepbound | 355 | $362,140 | $1,020 |
Tirzepatide in the states around Nebraska
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| Nebraska | 17 | $69/moWellmedr | 6,041 | Medicaid Zepbound: No |
| Colorado | 17 | $69/moWellmedr | 32,029 | Medicaid Zepbound: No |
| Iowa | 17 | $69/moWellmedr | 22,499 | Medicaid Zepbound: No |
| Kansas | 17 | $69/moWellmedr | 34,414 | Medicaid Zepbound: Yes |
| Missouri | 16 | $69/moWellmedr | 127,722 | Medicaid Zepbound: Yes |
| South Dakota | 17 | $69/moWellmedr | 7,486 | Medicaid Zepbound: No |
| Wyoming | 17 | $69/moWellmedr | 738 | Medicaid Zepbound: No |



